{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T18:55:12Z","timestamp":1649098512466},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,3,17]],"date-time":"2012-03-17T00:00:00Z","timestamp":1331942400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s11864-012-0187-3","type":"journal-article","created":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T11:38:16Z","timestamp":1331897896000},"page":"240-248","source":"Crossref","is-referenced-by-count":0,"title":["Patients With Positive Axillary Lymph Nodes: How to Use Genomic Assays"],"prefix":"10.1007","volume":"13","author":[{"given":"Ruta","family":"Rao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,17]]},"reference":[{"key":"187_CR1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747\u201352.","journal-title":"Nature"},{"key":"187_CR2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H","volume":"63","author":"CL Carter","year":"1989","unstructured":"Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181\u20137.","journal-title":"Cancer"},{"key":"187_CR3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00000478-199104000-00002","volume":"15","author":"DL Page","year":"1991","unstructured":"Page DL. Prognosis and breast cancer recognition of lethal and favorable prognostic types. Am J Surg Pathol. 1991;15:334\u201349.","journal-title":"Am J Surg Pathol"},{"key":"187_CR4","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.1989.7.9.1239","volume":"7","author":"PP Rosen","year":"1989","unstructured":"Rosen PP, Groshen S, Saigo PE, et al. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow up of 18\u00a0years. J Clin Oncol. 1989;7:1239\u201351.","journal-title":"J Clin Oncol"},{"key":"187_CR5","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687\u2013717.","journal-title":"Lancet"},{"key":"187_CR6","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/bjc.1998.581","volume":"78","author":"H Joensuu","year":"1998","unstructured":"Joensuu H, Pylkkanen L, Toikkanen S. Long-term survival in node-positive breast cancer treated by locoregional therapy alone. Br J Cancer. 1998;78:795\u20139.","journal-title":"Br J Cancer"},{"key":"187_CR7","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Version 2.2011. Available at http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf . Accessed December 2011."},{"key":"187_CR8","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes \u2013 dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736\u201347.","journal-title":"Ann Oncol"},{"key":"187_CR9","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxfien-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817\u201326.","journal-title":"N Engl J Med"},{"key":"187_CR10","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","volume":"24","author":"S Paik","year":"2006","unstructured":"Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726\u201334.","journal-title":"J Clin Oncol"},{"key":"187_CR11","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","volume":"25","author":"L Harris","year":"2007","unstructured":"Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 Update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287\u2013312.","journal-title":"J Clin Oncol"},{"key":"187_CR12","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/annonc\/mdp322","volume":"20","author":"A Goldhirsch","year":"2009","unstructured":"Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319\u201329.","journal-title":"Ann Oncol"},{"key":"187_CR13","doi-asserted-by":"crossref","first-page":"8623","DOI":"10.1158\/1078-0432.CCR-05-0735","volume":"11","author":"MA Cobleigh","year":"2005","unstructured":"Cobleigh MA, Tabesh B, Bitterman P, et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005;11:8623\u201331.","journal-title":"Clin Cancer Res"},{"key":"187_CR14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","volume":"11","author":"K Albain","year":"2010","unstructured":"Albain K, Barlow W, Shak S, et al. Prognositc and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, estrogen receptor positive breast cancer on chemotherapy: A retrospective analysis of a randomized trial. Lancet Oncol. 2010;11:55\u201365.","journal-title":"Lancet Oncol"},{"key":"187_CR15","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2009.24.4798","volume":"28","author":"M Dowsett","year":"2010","unstructured":"Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene Recurrence Score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC Study. J Clin Oncol. 2010;28:1829\u201334.","journal-title":"J Clin Oncol"},{"key":"187_CR16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","volume":"415","author":"LJ Veer van\u2019t","year":"2002","unstructured":"van\u2019t Veer LJ, Dai H, van de Vijver, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530\u20136.","journal-title":"Nature"},{"key":"187_CR17","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","volume":"347","author":"MJ Vijver van de","year":"2002","unstructured":"van de Vijver MJ, He YD, van\u2019t Veer LJ, et al. A gene expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999\u20132009.","journal-title":"N Engl J Med"},{"key":"187_CR18","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2001.19.18.3817","volume":"19","author":"A Goldhirsch","year":"2001","unstructured":"Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. J Clin Oncol. 2001;19:3817\u201327.","journal-title":"J Clin Oncol"},{"key":"187_CR19","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/jnci\/93.13.979","volume":"93","author":"P Eifel","year":"2001","unstructured":"Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1\u20133, 2000. J Natl Cancer Inst. 2001;93:979\u201389.","journal-title":"J Natl Cancer Inst"},{"key":"187_CR20","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jnci\/djj329","volume":"98","author":"M Buyse","year":"2006","unstructured":"Buyse M, Loi S, van\u2019t Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006;98:1183\u201392.","journal-title":"J Natl Cancer Inst"},{"key":"187_CR21","unstructured":"Adjuvant! Online. Available at http:\/\/www.adjuvantonline.com . Accessed December 2011."},{"key":"187_CR22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10549-008-0191-2","volume":"117","author":"JM Bueno-de-Mesquita","year":"2009","unstructured":"Bueno-de-Mesquita JM, Linn SC, Keijzer R, et al. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat. 2009;117:483\u201395.","journal-title":"Breast Cancer Res Treat"},{"key":"187_CR23","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10549-009-0333-1","volume":"119","author":"ME Straver","year":"2010","unstructured":"Straver ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2010;119:551\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"187_CR24","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10549-010-0814-2","volume":"120","author":"M Knauer","year":"2010","unstructured":"Knauer M, Mook S, Rutgers EJ, et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat. 2010;120:655\u201361.","journal-title":"Breast Cancer Res Treat"},{"key":"187_CR25","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10549-008-0130-2","volume":"116","author":"S Mook","year":"2009","unstructured":"Mook S, Schmidt MK, Viale G, et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat. 2009;116:295\u2013302.","journal-title":"Breast Cancer Res Treat"},{"key":"187_CR26","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.bjc.6602794","volume":"93","author":"B Weigelt","year":"2005","unstructured":"Weigelt B, Wessels LF, Bosma AJ, et al. No common denominator for breast cancer lymph node metastasis. Br J Cancer. 2005;93:924\u201332.","journal-title":"Br J Cancer"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-012-0187-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-012-0187-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-012-0187-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:34:24Z","timestamp":1559432064000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-012-0187-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,17]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["187"],"URL":"https:\/\/doi.org\/10.1007\/s11864-012-0187-3","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,17]]}}}